Group 1: Financial Performance - The company's Q1 2023 and Q1 2024 performance was poor, primarily due to the "de-inventory" trend in the plant protection industry, leading to a reduction in orders and revenue decline [1] - The company expects the "de-inventory" trend to slow down in the second half of the year, with a recovery in patented products compared to generic products [1] - The company is actively communicating with clients to maintain strategic relationships and mitigate the impact of "de-inventory" [1] Group 2: Business Development - The company has established a CRO team to enhance customer service and increase client retention, with the CRO business progressing as planned [2] - In the renewable energy sector, the company is conducting R&D and pilot production, aiming to leverage its chemical industry experience for future success [2] - The UK subsidiary is undergoing production line modifications and is actively seeking new clients and products to drive growth [2] Group 3: International Expansion - The company has signed a purchase intention for industrial land in Malaysia and is adjusting the construction schedule based on specific orders [2] - The Malaysian factory and UK subsidiary will work together to enhance international competitiveness and support the "going out" strategy [2] Group 4: ESG Initiatives - The company is implementing ESG measures, particularly in its pharmaceutical subsidiary, which includes carbon emission management [3] - Future ESG efforts will be promoted company-wide based on existing experiences and results, with targeted disclosures to meet regulatory and stakeholder needs [3]
联化科技(002250) - 2024年6月5日投资者关系活动记录表